Immuneering Corp
NASDAQ:IMRX
Fundamental Analysis

Revenue & Expenses Breakdown
Immuneering Corp
Balance Sheet Decomposition
Immuneering Corp
Current Assets | 38.2m |
Cash & Short-Term Investments | 35.9m |
Other Current Assets | 2.3m |
Non-Current Assets | 12.5m |
PP&E | 4.6m |
Intangibles | 7m |
Other Non-Current Assets | 810.9k |
Free Cash Flow Analysis
Immuneering Corp
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Immuneering Corp
Revenue
|
0
USD
|
Operating Expenses
|
-64.3m
USD
|
Operating Income
|
-64.3m
USD
|
Other Expenses
|
2.6m
USD
|
Net Income
|
-61.7m
USD
|
IMRX Profitability Score
Profitability Due Diligence
Immuneering Corp's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Immuneering Corp's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
IMRX Solvency Score
Solvency Due Diligence
Immuneering Corp's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Immuneering Corp's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMRX Price Targets Summary
Immuneering Corp
According to Wall Street analysts, the average 1-year price target for IMRX is 13.06 USD with a low forecast of 8.08 USD and a high forecast of 22.05 USD.
Dividends
Current shareholder yield for IMRX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?